Mirapex (pramipexole dihydrochloride) tablets
The purpose of
this letter is to advise you that effective May 1, 2005, Boehringer
Ingelheim Pharmaceuticals, Inc. (BIPI), will be the exclusive
promoter of Mirapex (pramipexole) in the US. As such, BIPI's newly
expanded Neurology sales force will be responsible for all field
support on this brand; the Pfizer field force will no longer be
providing field support for the product.
This was a
joint decision made by BIPI and Pfizer. The companies have been
working together to ensure that the transition occurs without
disruption to patients, caregivers and healthcare professionals. The
change will have no impact on the availability of your retail
stocking or sales of MIRAPEX. Please note that the MIRAPEX label will
change and the wording "co-marketed by Boehringer Ingelheim
Pharmaceuticals, Inc. and Pfizer Inc," will be removed.
We are excited
about this transition to our expanded Neurology sales force. It is
our strong belief that this expansion will help assure the continued
growth of the MIRAPEX brand. We look forward to working with our
retail partners to ensure that this transition goes smoothly.
Robert W. Belknap
Director, Trade Relations
Ingelheim Pharmaceuticals, Inc.